Metharbital
This barbiturate anticonvulsant was used to control seizures in epilepsy patients, working by enhancing the inhibitory effects of GABA in the brain to reduce abnormal electrical activity. Like other barbiturates, it carries risks of dependence, respiratory depression, and numerous drug interactions, leading to its replacement by safer anticonvulsants.
Molecular Weight
198.2200 g/mol
LogP
1.20
TPSA
66.50 Ų
Lipinski RO5
Pass
Mechanism of Action
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D Structure
Cite this structure
Embed this structure
SMILES
CCC1(CC)C(=O)NC(=O)N(C)C1=O
InChI
InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)
Molecular Formula
C9H14N2O3
HBD / HBA
1 / 3
Rotatable Bonds
2
Heavy Atoms
14
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This barbiturate anticonvulsant was used to control seizures in epilepsy patients, working by enhancing the inhibitory effects of GABA in the brain to reduce abnormal electrical activity. Like other barbiturates, it carries risks of dependence, respiratory depression, and numerous drug interactions, leading to its replacement by safer anticonvulsants.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Metharbital is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL450. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 4099. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="metharbital"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/metharbital/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/metharbital/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/metharbital/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="metharbital"></drugfyi-drug>